D. Gary Gilliland has served as a director of the Company since April 1, 2014. Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center, a research organization, in Seattle, WA since January 31, 2020. From January 2, 2015 to January 30, 2020, Dr. Gilliland previously served as President and Director of the Fred Hutchinson Cancer Research Center. Prior to that, he was the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine from October 2013 to January 2015, where he was responsible for synthesizing research and clinical-care initiatives across all medical disciplines including cancer, heart and vascular medicine, neurosciences, genetics, and pathology, to create a national model for the delivery of precise, personalized medicine. From 2009 until he joined Penn Medicine in 2013, Dr. Gilliland was Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. At Merck, Dr. Gilliland oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials that included the development of pembrolizumab (anti-PD1) for treatment of cancer, and managed all preclinical and clinical oncology-licensing activities. Prior to joining Merck, Dr. Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute from 1996 to 2009, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center from 2002 to 2009, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute from 2004 to 2009. Dr. Gilliland has a Ph.D. in Microbiology from UCLA and an M.D. from UCSF. He is board-certified in Internal Medicine and had his Fellowship training in Hematology and Oncology, each at Harvard Medical School. He is a Fellow of the American Association for Cancer Research (AACR), and is an elected member of the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), the American Academy of Arts of Sciences (AAAS) and the National Academy of Medicine (NAM).

Kerrii B. Anderson has served as a director of the Company since May 17, 2006. Ms. Anderson is the former Chief Executive Officer, President and Chief Financial Officer of Wendy’s International. Prior to joining Wendy’s in 2000, she was senior vice president and chief financial officer for 14 years for M/I Schottenstein Homes, Inc., a NYSE company that builds single-family homes.

Ms. Anderson has served as a director of Abercrombie & Fitch Co. since February 2018, The Sherwin-Williams Company since April 2019, and Worthington Industries, Inc. since September 2010. She was previously a director of the board of Chiquita Brands International from 2009 to 2012, and was chairwoman of the board from 2012 until the company’s acquisition in 2015. She was also a member of the board of P.F. Chang’s China Bistro from 2009 to 2012. Ms. Anderson also serves on the boards of the following non-profit entities: The Columbus Foundation and Elon University Board of Trustees.

Ms. Anderson has a strong record of leadership in operations, strategy, finance and talent management as a result of her experience at Wendy’s. Ms. Anderson also has significant expertise in the areas of accounting and financial reporting, corporate finance, corporate governance, and executive compensation through her service on other large public company boards. The breadth of experience enables Ms. Anderson to advise our Board on a variety of matters related to global operations and business strategy.

Sandy van der Vaart has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Labcorp since February 2020.

Prior to her current role with the company, Sandy served as Senior Vice President, Global General Counsel, Chief Compliance Officer and Corporate Secretary. Previously, she served as Labcorp’s Senior Vice President, Deputy Chief Legal Officer from 2015 to 2019 and Senior Vice President, General Counsel and Assistant Secretary from 2009 to 2015. She has been with Labcorp since 2001 and has held various other roles within the legal department.

Before joining Labcorp, Sandy was a member of the healthcare practice group with Smith, Helms, Mulliss & Moore and previously worked for the North Carolina Medical Society as Director of the society’s managed care department.

Sandy is a member of the Association of Corporate Counsel, the Society for Corporate Governance, and is the Chair for the NC Chamber Legal Institute. She previously served as Chair of the Health Law Section Council of the North Carolina Bar Association and as President of the North Carolina Society of Healthcare Attorneys. Sandy obtained her Bachelor of Science in nursing from the University of North Carolina at Chapel Hill and her Juris Doctorate from the University of Virginia School of Law.

In October 2024, Lance Berberian announced his planned retirement from Labcorp in 2025. Lance served as Executive Vice President and Chief Information and Technology Officer from 2014 through October 2024. In November 2024, he stepped into the role of Special Advisor, Strategy. In this role he is working directly with the CEO and the executive team to drive the development and implementation of Labcorp’s enterprise strategy.

Before Labcorp, Lance was the Chief Information Officer at IDEXX Laboratories, Inc., a global leader in diagnostics and IT solutions for animal health and food and water quality. Lance also served as Chief Information Officer and President of Kellstrom Defense Aerospace Inc., a fully integrated supply chain firm, from 2000 to 2007. Prior to that, he was the Chief Information Officer of Interim HealthCare Inc. from 1997 to 2000.

Lance serves as chair of the strategic advisory board for North Carolina State University’s Department of Computer Science. He also serves on the Board of Trustees for Elon University. Lance holds a Bachelor of Science in both business administration and information technology from Thomas Edison State College.

In November 2024, Glenn Eisenberg announced his planned retirement from Labcorp, effective April 30, 2025. Glenn served as Executive Vice President and Chief Financial Officer (CFO) since 2014. In December 2024, Glenn assumed the role as Special Advisor to the CEO to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

Prior to joining Labcorp, he served as Executive Vice President, Finance and Administration, and Chief Financial Officer at The Timken Company, a leading global manufacturer of engineered bearings and power transmission products. Previously, he served as President and Chief Operating Officer of United Dominion Industries, a global diversified industrial company, after working in several executive roles at the company, including Chief Financial Officer and President of its test instrumentation segment.

Glenn serves on the board of directors of Solventum Corporation, a global diversified healthcare company, and AMSURG, a nationally recognized leader in the strategic and operational management of surgery centers. He previously served on the public boards of directors of Family Dollar Stores, Inc., Perspecta Inc., US Ecology, Inc. and Alpha Natural Resources, Inc.. He received his Bachelor of Arts from Tulane University and his Master of Business Administration from Georgia State University.

Adam Schechter became chief executive officer of Labcorp (NYSE: LH) in November 2019 and chairman in May 2020. Previously, Schechter was named lead independent director in January 2019 after serving on the board since 2013.

Under Schechter’s leadership, Labcorp, a leading global life sciences company with more than 80,000 employees, harnesses science, innovation and technology to improve health and improve lives. Through its strong diagnostics and drug development capabilities, vast health data and insights, and extensive global laboratory network, the company advances healthcare across all major clinical and therapeutic areas, including oncology, Alzheimer’s, autoimmune and liver diseases, and more.

Labcorp is helping customers bring innovative, life-changing treatments and vaccines to market by leveraging its combined expertise in drug development and diagnostics. With these capabilities, Schechter, with his colleagues at Labcorp, created a model for addressing emerging health crises with their response to the COVID-19 pandemic and the Monkeypox virus.

Schechter joined Labcorp after a long and distinguished career at Merck, where he served as executive vice president and president of global human health and was a member of the executive committee. At Merck, among other accomplishments, Schechter focused on ensuring that Merck’s medicines and vaccines were available to people around the world, led a large global organization across the spectrum of commercial operations, transformed Merck’s commercial model, and led the integration of Merck and Schering-Plough.

He is the vice chair of the Board of Directors for the American Clinical Laboratory Association (ACLA), a board member for Water.org, and serves as an independent director on the board of DaVita, Inc. Schechter is chair of the Corporate Advisory Council for the National Alliance for Hispanic Health, a longtime leader and advocate on Hispanic issues and an Executive Advisor to its Healthy Americas Foundation.

Schechter holds a Bachelor of Arts in Biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from the university in 2021.